Wissenschaftliche Arbeiten

Uzm. Dr. Aslı Geçgel

47 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

    Cancers, 2026

    DOI 10.3390/cancers18182987 PMID 42794953 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study

    Targeted Oncology, 2026

    DOI 10.1007/s11523-026-01261-w PMID 42907609 Quelle: OpenAlex

  3. Treatment Outcomes and Toxicity of Cisplatin–Etoposide-Based Regimens and Carboplatin–Paclitaxel as Adjuvant Chemotherapy for Ovarian Adult Granulosa Cell Tumors: A Multicenter Retrospective Cohort Study

    Cancers, 2026

    DOI 10.3390/cancers18182910 PMID 42794877 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Clinical Outcomes of Lenvatinib-Pembrolizumab in a High-Risk, Dual ICI-Refractory Melanoma Cohort

    Clinical Medicine Insights. Oncology, 2026

    DOI 10.1177/11795549261472694 PMID 42523965 Frei zugänglicher VolltextQuelle: Europe PMC

  5. Is IMvigor011 a conventional adjuvant trial or a ctDNA-triggered preemptive treatment strategy?

    Future oncology (London, England), 2026

    DOI 10.1080/14796694.2026.2746184 PMID 42844909 Quelle: Europe PMC

  6. Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study

    Breast cancer (Dove Medical Press), 2026

    DOI 10.2147/bctt.s629176 PMID 42518661 Frei zugänglicher VolltextQuelle: Europe PMC

  7. A hidden danger in cancer patients: intestinal parasites

    Turkish journal of medical sciences, 2026

    DOI 10.55730/1300-0144.6370 PMID 42677300 Frei zugänglicher VolltextQuelle: Europe PMC

  8. Impact of prognostic nutritional index and geriatric nutritional risk index on prognosis in elderly patients with early-stage prostate cancer

    Frontiers in Nutrition, 2026

    DOI 10.3389/fnut.2026.1745718 PMID 41783818 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  9. Survival Patterns in Early-onset Colorectal Cancer Receiving Adjuvant Capecitabine Based Therapy

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-11-8 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Predicting 10-year survival in early and locally advanced breast cancer: prognostic value of nutritional status and body composition

    Nutrition, 2026

    DOI 10.1016/j.nut.2026.113133 PMID 41775036 Quelle: OpenAlex

  11. Methodological Considerations in the PENINSULA First-Line Pleural Mesothelioma Study: Endpoints, Imaging Review, and Safety

    SSRN Electronic Journal, 2026

    DOI 10.2139/ssrn.6142089 Frei zugänglicher VolltextQuelle: OpenAlex

  12. Treatment paradigms in undifferentiated pleomorphic sarcoma of bone: lessons learned from osteosarcoma and questions that remain commentary on: Bielack SS et al. J Cancer Res Clin Oncol (2026)

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-026-06456-2 PMID 41874771 Frei zugänglicher VolltextQuelle: OpenAlex

  13. Primary Tumor Histologic Regression and Immunotherapy Outcomes in Recurrent or Metastatic Melanoma

    Cancer Investigation, 2026

    DOI 10.1080/07357907.2026.2739846 PMID 42831536 Frei zugänglicher VolltextQuelle: OpenAlex

  14. Risk factors for dry eye disease in adult granulosa cell tumors: Implications for quality of life

    Ege Tıp Dergisi, 2026

    DOI 10.19161/etd.1802914 Frei zugänglicher VolltextQuelle: OpenAlex

  15. 150P Adjuvant BEP/EP versus carboplatin-paclitaxel in adult granulosa cell tumor of the ovary: A multicenter analysis of survival and toxicity

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.108197 Frei zugänglicher VolltextQuelle: OpenAlex

  16. HIV Seroprevalence and Screening Practices Among Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Study From Türkiye

    Journal of Clinical Practice and Research, 2026

    DOI 10.14744/cpr.2026.64997 PMID 42676394 Frei zugänglicher VolltextQuelle: OpenAlex

  17. Kanserde Takip

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716 Frei zugänglicher VolltextQuelle: OpenAlex

  18. Efficacy of Subsequent Therapy in Patients with Hormone-Positive Advanced Breast Cancer with Disease Progression After CDK4/6 Inhibitor Therapy: Multicenter Real-Life Data

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14207376 PMID 41156245 Frei zugänglicher VolltextQuelle: ORCID

  19. Prognostic Value of Preoperative Lymphocyte-to-Monocyte Ratio in Patients with Recurrent Colorectal Cancer

    Medicina, 2025

    DOI 10.3390/medicina61040707 PMID 40282998 9 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  20. Is Mandard tumor regression grade scoring sufficient for locally advanced rectal cancer?

    Medical Science and Discovery, 2025

    DOI 10.36472/msd.v12i1.1228 Frei zugänglicher VolltextQuelle: ORCID

  21. KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort

    Journal of clinical medicine, 2025

    DOI 10.3390/jcm14196826 PMID 41095904 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  22. Prognostic Value of CONUT and ALBI in Metastatic Pancreatic Cancer: A Retrospective Cohort Study

    Diagnostics (Basel, Switzerland), 2025

    DOI 10.3390/diagnostics15243161 PMID 41464163 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  23. Prognostic Power of the Naples Score in Non-Small Cell Lung Cancer: Can Inflammation and Nutrition Predict Survival?

    Journal of clinical medicine, 2025

    DOI 10.3390/jcm14113715 PMID 40507476 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  24. Systemic Immune-Inflammation Index as a Prognostic Marker in Gastric and Gastroesophageal Junction Cancers Receiving Perioperative FLOT Therapy

    Medicina (Kaunas, Lithuania), 2025

    DOI 10.3390/medicina61091614 PMID 41011005 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  25. Predicting immune-related adverse events in patients with melanoma: the role of interleukin-7 rs16906115 polymorphism and lymphocyte dynamics

    Frontiers in Immunology, 2025

    DOI 10.3389/fimmu.2025.1616325 PMID 40642097 9 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  26. Skeletal muscle index as a prognostic biomarker for survival in HER2-positive and triple-negative breast cancer: a retrospective cohort study

    BMJ Supportive & Palliative Care, 2025

    DOI 10.1136/spcare-2025-005991 PMID 41476001 2 Zitationen (OpenAlex) Quelle: OpenAlex

  27. Malignant transformations in mature cystic teratomas: A case report and literature review

    Medicine International, 2025

    DOI 10.3892/mi.2025.251 PMID 40697355 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  28. Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study

    Annals of Saudi Medicine, 2025

    DOI 10.5144/0256-4947.2025.249 PMID 40753462 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  29. GLR in Cholangiocarcinoma: A Practical Biomarker in Need of Validation

    Nutrition and Cancer, 2025

    DOI 10.1080/01635581.2025.2570558 PMID 41074758 1 Zitation (OpenAlex) Quelle: OpenAlex

  30. What impact does therapy selection have on the course of clinical outcomes for recurrent gliomas?

    The Annals of Clinical and Analytical Medicine, 2025

    DOI 10.4328/acam.22208 Frei zugänglicher VolltextQuelle: OpenAlex

  31. Is the Combination of Pembrolizumab and Regorafenib the Beginning of a New Era in the Treatment of Metastatic Colorectal Cancer?

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-23 Frei zugänglicher VolltextQuelle: OpenAlex

  32. Ten-Year Real-World Outcomes and Clinicopathologic Predictors of Recurrence in Adult Granulosa Cell Tumors: A Turkish Single-Center Experience

    Current Oncology, 2025

    DOI 10.3390/curroncol32090504 PMID 41002574 Frei zugänglicher VolltextQuelle: OpenAlex

  33. 10-Year prognostic value of body composition in breast cancer: Implications for treatment and survival

    Clinical Nutrition ESPEN, 2025

    DOI 10.1016/j.clnesp.2025.07.395 Quelle: OpenAlex

  34. Body Mass Index as an Independent Prognostic Factor in Second-Line Nivolumab Therapy for Metastatic Clear Cell Renal Cell Carcinoma

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-11-10 Frei zugänglicher VolltextQuelle: OpenAlex

  35. 393eP A viral footprint in tumor immunity: Anti-HBc IgG serostatus as a prognostic marker in melanoma

    Immuno-Oncology Technology, 2025

    DOI 10.1016/j.iotech.2025.101571 Frei zugänglicher VolltextQuelle: OpenAlex

  36. Meningioma-Medulloblastoma-Ependimoma

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716.c6080 Quelle: OpenAlex

  37. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim

    Akademisyen Kitabevi eBooks, 2024

    DOI 10.37609/akya.2380 Frei zugänglicher VolltextQuelle: OpenAlex

  38. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

    Medicine, 2024

    DOI 10.1097/md.0000000000038828 PMID 39058877 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  39. Assessment of Unwanted Side Effects of Vaccines in Cancer Patients: Where Do We Stand in Vaccination? Where Should Our Next Step Be?

    International Journal of Hematology and Oncology, 2024

    DOI 10.4999/uhod.247637 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  40. Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus Trametinib

    Balkan Medical Journal, 2024

    DOI 10.4274/balkanmedj.galenos.2024.2024-1-86 PMID 38572561 Frei zugänglicher VolltextQuelle: ORCID

  41. Pigmentation of the Tongue, Nails, and Gingiva Following Adriamycin Therapy: A Literature Review and Clinical Insights

    Medical Science and Discovery, 2024

    DOI 10.36472/msd.v11i3.1137 Frei zugänglicher VolltextQuelle: ORCID

  42. 16P Granulosa cell tumor of the ovary: 10-year follow-up data of 56 patients

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.102555 Frei zugänglicher VolltextQuelle: ORCID

  43. Genetic Perspective of Breast Cancer Patients: Implications for Family Members

    Springer eBooks, 2024

    DOI 10.1007/978-3-031-75480-7_5 Quelle: ORCID

  44. Pembrolizumab Associated Autoimmune Diabetes Mellitus: Case Series

    Namık Kemal Tıp Dergisi, 2024

    DOI 10.4274/nkmj.galenos.2024.48726 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  45. What impact does therapy selection have on the course of clinical outcomes for recurrent gliomas?

    MOJ Public Health, 2024

    DOI 10.15406/mojph.2024.13.00445 Quelle: OpenAlex

  46. Flavonoidler

    Akademisyen Kitabevi eBooks, 2024

    DOI 10.37609/akya.2380.c13887 Quelle: OpenAlex

  47. Living Donor Kidney Transplantation: Why Potential Donors and Recipients do not Achieve it. Malatya Algorithm

    Revista de Nefrologia, Dialisis Y Transplante, 2020

    Quelle: ORCID